Loading company…
Supernus develops and commercializes medicines for central nervous system disorders, including ADHD and epilepsy.
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system conditions, including ADHD and epilepsy. Its products include Qelbree™, a non-stimulant ADHD treatment. The company was established in 2005 and is based in Rockville, US. CEO Jack Khattar leads the company. Supernus completed an IPO in May 2012, raising USD 50 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in